2024 EULAR Points to consider when treating patients with cancer
2024 EULAR Points to consider when using targeted therapies in patients with inflammatory arthritis and a history of cancer
2024 EULAR Points to consider when using targeted therapies in patients with inflammatory arthritis and a history of cancer
A slides set on RA Treatment options with MTX teaching slides
The pros and cons of Private Practice vs. Academic Medicine. - submitted by Kathryn Dao, MD
Distinguishing features between the 2021 ACR and 2022 EULAR RA treatment guidelines
Oral Surveillance study resulted in a new FDA drug safety bulleting 9/21/21 and since the label for all JAK inhibitors has changed (FDA, Canada) or will change (EMA).